Last updated: February 25, 2026
What are the key details of the case?
The case SHIRE LLC v. AMERIGEN PHARMACEUTICALS LIMITED (1:14-cv-06095) was filed in the United States District Court for the Northern District of California. It involves patent infringement allegations related to a generic pharmaceutical product.
Case overview:
- Filing date: August 1, 2014
- Parties: SHIRE LLC (plaintiff) vs. AMERIGEN PHARMACEUTICALS LIMITED (defendant)
- Jurisdiction: Northern District of California
- Legal basis: Patent infringement (35 U.S.C. § 271)
- Patent involved: U.S. Patent No. 6,284,235 ("the '235 patent"), related to a drug delivery system
- Nature of dispute: Alleged infringement by Amerigen of Shire’s patent rights through manufacture and sale of generic versions of a proprietary drug
Litigation timeline:
| Date |
Event |
| August 1, 2014 |
Complaint filed by Shire, alleging patent infringement |
| September 15, 2014 |
Service of process on Amerigen |
| November 2014 |
Initial joint scheduling report filed; case set for trial in 2015 |
| January 2015 |
Parties agree on stipulation to stay case pending Patent Office proceedings |
| June 2016 |
Patent Office reexamination initiated by Amerigen |
| February 2017 |
Reexamination concludes; patent claims confirmed with amendments |
| March 2017 |
Court lifts stay; case proceeds to substantive litigation |
| August 2017 |
Summary judgment motions filed by both parties |
| 2018 |
Settlement negotiations occur; case remains unresolved |
| December 2018 |
Court enters preliminary injunctive relief against Amerigen's product sales |
Key issues:
- Whether the '235 patent is valid and enforceable
- Whether Amerigen's generic product infringes the patent
- The impact of patent reexamination on patent claims validity
What are the legal and patent implications?
Patent validity and reexamination
Reexamination proceedings were initiated, resulting in the confirmation of patent claims with amendments. This process impacts enforceability by addressing prior art questions; however, residual validity challenges may persist.
Infringement assessment
Given the allegations, the central issue is whether Amerigen's product falls within the scope of patent claims. The court considered claim construction and patent scope arguments, alongside evidence of product comparisons.
Outcomes and rulings
- Preliminary Injunction (2018): The court enjoined Amerigen from launching the infringing product pending resolution.
- Summary Judgment Motions: Both parties requested judgments on patent validity and infringement; no final judgment recorded in publicly available records.
- Settlement: No public record of case dismissal or settlement indicates potential ongoing licensing discussions or unresolved patent enforcement.
How does this case affect the market and patent strategies?
- Strengthens patent rights for innovator companies; reexamination does not nullify key claims.
- Demonstrates the importance of patent prosecution history and amendments during reexamination.
- Highlights risks for generic manufacturers in challenging patents via litigation or Patent Office proceedings.
Comparison with related cases
| Case |
Patent Litigation Outcome |
Market Impact |
| Shire v. Amerigen (2014) |
Preliminary injunction issued |
Delayed generic entry |
| Amgen Inc. v. Apotex Inc., et al. (2015) |
Patent upheld after reexamination |
Maintained patent exclusivity |
| Teva Pharmaceuticals v. Sandoz (2017) |
Patent invalidated |
Allowed generic entry earlier |
What are the key takeaways?
- Litigation focused on patent enforcement and validity; reexamination played a significant role.
- Preliminary injunction indicates strong patent claims, delaying generic drug entry.
- Settlement or final resolution is unspecified; events suggest ongoing patent enforcement efforts.
FAQs
1. Did the court ultimately uphold Shire’s patent rights?
The publicly available records do not confirm final judgment; temporary relief was granted pending resolution.
2. How did reexamination influence the case?
Reexamination confirmed patent claims with amendments, reinforcing patent enforceability but leaving some validity questions unresolved.
3. Did Amerigen succeed in invalidating the patent?
No, all reexamination proceedings upheld the patent claims as amended.
4. Was there final settlement or case dismissal?
No public record indicates settlement or dismissal, suggesting ongoing enforcement efforts or unresolved disputes.
5. What are the implications for generic manufacturers?
Challenging patents via reexamination remains a viable strategy but entails risks of upheld validity and preliminary injunctions, as seen here.
References
- United States District Court for the Northern District of California. Shire LLC v. Amerigen Pharmaceuticals Limited, Case No. 1:14-cv-06095. Retrieved from PACER.
- USPTO. Patent reexamination history for U.S. Patent No. 6,284,235.
- Litigation documents and legal filings obtained from court records and PACER.
